Compare Ascendis Pharma A/S (ASND) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Global Clean Energy ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares Global Clean Energy ETF trades at $18.96. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | ICLN | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $23.75 |
52-Week Low | $163.32 | $13.37 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ICLN trades at $19.25, down 0.41% with a bearish technical signal from moving averages. The ETF shows strong 2026 performance with clean energy sector momentum driven by AI demand and high oil prices. Recent news highlights policy risks from US permit delays affecting $121 billion in renewable investments, while China's 2030 EV targets provide long-term growth catalysts. The fund offers global diversification across 105 clean energy holdings.
Outlook remains cautiously optimistic despite near-term policy headwinds. The structural shift toward clean energy infrastructure and growing global investment support long-term growth potential. Key risks include regulatory uncertainty and competitive pressure from traditional energy ETFs offering higher yields. Current levels may present accumulation opportunities for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
